Ocugen (NASDAQ:OCGN – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05), Zacks reports. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. During the same period in the prior year, the business earned ($0.03) earnings per share.
Ocugen Price Performance
Ocugen stock traded up $0.00 during mid-day trading on Wednesday, hitting $0.59. 658,340 shares of the company traded hands, compared to its average volume of 4,069,496. Ocugen has a one year low of $0.57 and a one year high of $2.11. The stock has a market cap of $172.17 million, a price-to-earnings ratio of -3.29 and a beta of 3.82. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The stock has a fifty day moving average price of $0.74 and a 200-day moving average price of $0.91.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on OCGN. Chardan Capital restated a “buy” rating and issued a $6.00 price objective on shares of Ocugen in a research report on Thursday, February 13th. HC Wainwright raised their price objective on shares of Ocugen from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, February 13th.
About Ocugen
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Featured Stories
- Five stocks we like better than Ocugen
- The Significance of Brokerage Rankings in Stock Selection
- Is Advanced Micro Devices Stock Slide Over?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Lemonade’s Q4 Surge: Has This AI-Powered Insurer Turned a Corner?
- How to Calculate Stock Profit
- 2 Energy Stocks to Play Both Sides of Tariff Uncertainty
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
